A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress
SPT-300-2024-204
Phase 2 other active
Quick answer
A 6-Week, Multicenter, Open-Label, Monotherapy, Extension Study of SPT-300 in Adults with Major Depressive Disorder, With or Without Anxious Distress for Major Depressive Disorder (MDD), with or without Anxious Distress is a Phase 2 program (other) at Seaport Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Seaport Therapeutics
- Indication
- Major Depressive Disorder (MDD), with or without Anxious Distress
- Phase
- Phase 2
- Modality
- other
- Status
- active